Tempus AI Shares Plunge 2.62% as Trading Volume Slumps to 175th in Activity Amid Strategic Moves

Tempus AI (TEM) fell 2.62% on September 3, 2025, with a trading volume of $540 million, a 24.14% drop from the previous day, ranking it 175th in market activity. The stock’s performance coincided with multiple corporate updates, including its participation in Morgan Stanley’s 23rd Annual Global Healthcare Conference on September 8-10. CEO Eric Lefkofsky and CFO Jim Rogers are scheduled to lead a fireside chat, potentially drawing investor attention as the company highlights its AI-driven precision medicine initiatives.

Tempus recently expanded its data capabilities through the acquisition of Paige, a digital pathology firm, which is expected to enhance its technical team and data resources. The move aligns with the company’s strategy to strengthen its AI portfolio in healthcare. Separately, the firm reported second-quarter 2025 results, with revenue rising 89.6% year-over-year to $314.6 million, driven by growth in genomics and data services. These financial updates were disclosed in early August, ahead of its scheduled earnings release on August 8.

The stock’s decline may reflect broader market dynamics or investor caution ahead of the conference and quarterly results. However, the acquisition of Paige and the company’s focus on AI-driven healthcare solutions could position Tempus for long-term growth, assuming execution aligns with strategic goals. The upcoming conference may offer insights into investor sentiment, particularly as key executives engage with analysts.

On September 3, Tempus traded at a 2.62% loss with a volume of $540 million, a 24.14% decrease from the prior day’s activity.